Free Trial

iTeos Therapeutics (ITOS) Earnings Date, Estimates & Call Transcripts

$18.09
+0.04 (+0.22%)
(As of 05/20/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Aug. 13Estimated
Actual EPS
(Mar. 6)
-$0.85 Beat By $0.18
Consensus EPS
(Mar. 6)
-$1.03
Skip Charts & View Estimated and Actual Earnings Data

ITOS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ITOS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

iTeos Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($1.22)($0.89)($1.06)
Q2 20242($1.15)($0.99)($1.07)
Q3 20242($1.21)($1.11)($1.16)
Q4 20242($1.25)($1.24)($1.25)
FY 20248($4.83)($4.23)($4.53)
Q1 20251($1.40)($1.40)($1.40)
Q2 20251($1.52)($1.52)($1.52)
Q3 20251($1.64)($1.64)($1.64)
Q4 20251($1.78)($1.78)($1.78)
FY 20254($6.34)($6.34)($6.34)

ITOS Earnings Date and Information

iTeos Therapeutics last released its quarterly earnings results on March 6th, 2024. The reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.03) by $0.18. iTeos Therapeutics has generated ($3.78) earnings per share over the last year (($3.78) diluted earnings per share). Earnings for iTeos Therapeutics are expected to decrease in the coming year, from ($4.57) to ($5.76) per share. iTeos Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.

iTeos Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/13/2024
Estimated)
------- 
3/6/2024Q4 2023($1.03)($0.85)+$0.18($0.85)$37.41 million-
11/7/2023Q3 2023($1.20)($0.90)+$0.30($0.90)--
8/8/2023Q2 2023($1.03)($0.96)+$0.07($0.96)--
5/10/2023Q1 2023($0.99)($0.44)+$0.55($0.44)$13.80 million$12.60 million
3/15/2023Q4 2022$0.42$0.57+$0.15$0.57$41.16 million$53.91 million
11/10/2022Q3 2022$0.07$0.03($0.04)$0.03$42.05 million$19.49 million
8/10/2022Q2 2022$1.20$0.15($1.05)$0.15$96.95 million$41.72 million
5/12/2022Q1 2022$0.80$1.82+$1.02$1.82$63.30 million$152.52 million    
3/23/2022Q4 2021$1.29$4.88+$3.59$4.88$85.45 million$240.50 million
11/10/2021Q3 2021$4.95$1.86($3.09)$1.86$329.75 million$104.27 million    
8/12/2021Q2 2021($0.41)($0.75)($0.34)($0.75)--    

iTeos Therapeutics Earnings - Frequently Asked Questions

When is iTeos Therapeutics's earnings date?

iTeos Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on ITOS's earnings history.

Did iTeos Therapeutics beat their earnings estimates last quarter?

In the previous quarter, iTeos Therapeutics (NASDAQ:ITOS) reported ($0.85) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.03) by $0.18. Learn more on analysts' earnings estimate vs. ITOS's actual earnings.

How much revenue does iTeos Therapeutics generate each year?

iTeos Therapeutics (NASDAQ:ITOS) has a recorded annual revenue of $12.60 million.

How much profit does iTeos Therapeutics generate each year?

iTeos Therapeutics (NASDAQ:ITOS) has a recorded net income of -$112.64 million. ITOS has generated -$3.78 earnings per share over the last four quarters.

What is iTeos Therapeutics's EPS forecast for next year?

iTeos Therapeutics's earnings are expected to decrease from ($4.57) per share to ($5.76) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ITOS) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners